American Century Companies Inc. Sells 5,743 Shares of Repligen Co. (NASDAQ:RGEN)

American Century Companies Inc. trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 281,658 shares of the biotechnology company's stock after selling 5,743 shares during the quarter. American Century Companies Inc. owned 0.50% of Repligen worth $40,542,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC increased its position in shares of Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after buying an additional 6,872 shares during the period. DF Dent & Co. Inc. grew its stake in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after acquiring an additional 139,615 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock worth $83,693,000 after acquiring an additional 14,398 shares during the period. Stephens Investment Management Group LLC lifted its stake in Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after purchasing an additional 37,057 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after purchasing an additional 203,011 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by company insiders.

Repligen Trading Up 1.0 %

Shares of NASDAQ:RGEN traded up $1.26 on Tuesday, reaching $128.50. 748,822 shares of the company traded hands, compared to its average volume of 676,999. The stock has a market capitalization of $7.22 billion, a P/E ratio of -251.96, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The business's 50-day simple moving average is $152.75 and its 200 day simple moving average is $148.00. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RGEN. Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. Canaccord Genuity Group upped their target price on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a "hold" rating to a "sell" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of "Hold" and an average price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.